I'm LongbridgeAI, I can summarize articles.A high-margin oncology platform is scaling commercial adoption of its FDA-cleared RenovoCath device, targeting a $400M+ U.S. market and expanding into new indications. Interim Phase III data show a 6-month survival benefit and fewer adverse events in pancreatic cancer, supporting strong revenue growth and future label expansion.Original document: RenovoRx, Inc. [RNXT] Slides Release — Sep. 14 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
A high-margin oncology platform is scaling commercial adoption of its FDA-cleared RenovoCath device, targeting a $400M+ U.S. market and expanding into new indications. Interim Phase III data show a 6-month survival benefit and fewer adverse events in pancreatic cancer, supporting strong revenue growth and future label expansion.
Original document: RenovoRx, Inc. [RNXT] Slides Release — Sep. 14 2026